Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study

Antonello Pinto, MD, Vincenzo Pavone, MD, Francesco Angrilli, MD, Mariangela Saggese, PharmD, Stefania Crisci, ScD, Caterina Patti, MD, Pier Luigi Zinzani, MD PhD, Alfonso Maria D'Arco, MD, Elena Cavalieri, MD, Attilio Guarini, MD, Michele Spina, MD, Daniela Carlino, MD, Simona Falorio, MD, Emanuela Morelli, MD, Manuela Arcamone, MD, Ferdinando Frigeri, MD PhD, Annarosaria De Chiara, MD, Rosaria De Filippi, MD PhD, Gaetano Corazzelli, MD

Blood (2015) 126 (23): 1541.

https://doi.org/10.1182/blood.V126.23.1541.1541

Published: 2015

Journal Articles

Continuous Exposure to Bendamustine (BDM) Results in Stable Upregulation of CD30 and Increased Sensitivity to Brentuximab Vedotin (BV) in Tumor Cells of Hodgkin Lymphoma (HL)

Rosaria De Filippi, MD PhD, Michele Cillo, ScD, Stefania Crisci, ScD, Sara Mele, BS, Serena Zanotta, ScD, Angela De Monaco, ScD, Domenico Galati, MD, Giancarla Iaccarino, ScD, Raffaele Di Francia, ScD, Emanuela Morelli, MD, Gianpaolo Marcacci, MD, Cristina Becchimanzi, MD, Attilio Guarini, MD, Ferdinando Frigeri, MD PhD, Gaetano Corazzelli, MD, Antonello Pinto, MD

Blood (2015) 126 (23): 2479.

https://doi.org/10.1182/blood.V126.23.2479.2479

Published: 2015

Journal Articles

The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

Rosaria De Filippi, MD PhD, Stefania Crisci, ScD, Michele Cillo, ScD, Sara Mele, BS, Angela De Monaco, ScD, Domenico Galati, MD, Serena Zanotta, ScD, Gaetana Capobianco, MD, Francesco Volzone, MD, Manuela Arcamone, MD, Piera Maiolino, PharmD, Mariangela Saggese, PharmD, Gaetano Corazzelli, MD, Ferdinando Frigeri, MD PhD, Thomas Mehrling, MD PhD, Antonello Pinto, MD

Blood (2015) 126 (23): 2481.

https://doi.org/10.1182/blood.V126.23.2481.2481

Published: 2015

Journal Articles

Molecular Determinants of Bendamustine (BDM) Toxicity towards Hodgkin (H) and Reed-Sternberg (RS) Cell Lines From Hodgkin Lymphoma (HL).

Rosaria De Filippi, MD, PhD, Stefania Crisci, PhD, Ferdinando Frigeri, MD, PhD, Donatella Aldinucci, PhD, Domenico Galati, MD, Rosa Calemma, PhD, Giulio Abagnale, PhD, Gaetana Capobianco, MD, Manuela Arcamone, MD, Raffaele Di Francia, DPharm, Laura Mettivier, MD, Mariangela Saggese, PhD, Gaetano Corazzelli, MD, Antonio Pinto, MD

Blood (2012) 120 (21): 2763.

https://doi.org/10.1182/blood.V120.21.2763.2763

Published: 2012

Journal Articles

Peptide Nucleic Acid (PNA)-Clamping Competitive PCR: A New Tool for the High Sensitive Detection of JAK2V617F Mutation in Myeloproliferative Neoplasms (MPNs)

Ferdinando Frigeri, MD, PhD, Raffaele Di Francia, PhD, Luigi Petraccone, PhD, Concetta Giancola, PhD, Annunziata Cummaro, PhD, Paolo Danise, MD, Stefania Crisci, PhD, Giancarla Iaccarino, PhD, Rosaria De Filippi, MD, PhD, Emanuela Morelli, MD, Gaetana Capobianco, MD, Francesco Volzone, MD, Alfonso Maria D'Arco, MD, Antonio Pinto, MD

Blood (2011) 118 (21): 5168.

https://doi.org/10.1182/blood.V118.21.5168.5168

Published: 2011

Journal Articles

Abnormalities in Serum Free-Immunoglobulin Light Chains Show a High and Differential Frequency among WHO Subtypes of B-Cell Non-Hodgkin’s Lymphoma (NHL) and May Turn of Value for Therapeutic Monitoring: A Study of 354 Newly Diagnosed Patients

Antonio Pinto, MD, Rosaria De Filippi, MD, PhD, Giancarla Iaccarino, D.Sci, Raffaele Di Francia, D.Sci, Mariarosaria Distinto, D.Sci, Ferdinando Frigeri, MD, PhD, Filippo Russo, MD, Alessandro Marchei, D.Sci, Barbara Amoroso, MD

Blood (2008) 112 (11): 2813.

https://doi.org/10.1182/blood.V112.11.2813.2813

Published: 2008

NARROW

Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study

Continuous Exposure to Bendamustine (BDM) Results in Stable Upregulation of CD30 and Increased Sensitivity to Brentuximab Vedotin (BV) in Tumor Cells of Hodgkin Lymphoma (HL)

The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

Molecular Determinants of Bendamustine (BDM) Toxicity towards Hodgkin (H) and Reed-Sternberg (RS) Cell Lines From Hodgkin Lymphoma (HL).

Peptide Nucleic Acid (PNA)-Clamping Competitive PCR: A New Tool for the High Sensitive Detection of JAK2V617F Mutation in Myeloproliferative Neoplasms (MPNs)

Abnormalities in Serum Free-Immunoglobulin Light Chains Show a High and Differential Frequency among WHO Subtypes of B-Cell Non-Hodgkin’s Lymphoma (NHL) and May Turn of Value for Therapeutic Monitoring: A Study of 354 Newly Diagnosed Patients

Email alerts

ASH Publications

American Society of Hematology

Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study

Continuous Exposure to Bendamustine (BDM) Results in Stable Upregulation of CD30 and Increased Sensitivity to Brentuximab Vedotin (BV) in Tumor Cells of Hodgkin Lymphoma (HL)

The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

Molecular Determinants of Bendamustine (BDM) Toxicity towards Hodgkin (H) and Reed-Sternberg (RS) Cell Lines From Hodgkin Lymphoma (HL).

Peptide Nucleic Acid (PNA)-Clamping Competitive PCR: A New Tool for the High Sensitive Detection of JAK2V617F Mutation in Myeloproliferative Neoplasms (MPNs)

Abnormalities in Serum Free-Immunoglobulin Light Chains Show a High and Differential Frequency among WHO Subtypes of B-Cell Non-Hodgkin’s Lymphoma (NHL) and May Turn of Value for Therapeutic Monitoring: A Study of 354 Newly Diagnosed Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only